AU4363200A - Soluble tumor necrosis factor receptor treatment of medical desorders - Google Patents

Soluble tumor necrosis factor receptor treatment of medical desorders Download PDF

Info

Publication number: AU4363200A
Authority: AU; Australia
Prior art keywords: tnfr; administered; psoriasis; patient; dose
Prior art date: 1999-04-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU43632/00A

Other languages

English (en)

Inventor

Barbara K. Finck

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Immunex Corp

Original Assignee

Immunex Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-19

Filing date

2000-04-19

Publication date

2000-11-02

2000-04-19 Application filed by Immunex Corp filed Critical Immunex Corp

2000-11-02 Publication of AU4363200A publication Critical patent/AU4363200A/en

Status Abandoned legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims description 45
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 title claims description 36
102000003298 tumor necrosis factor receptor Human genes 0.000 title claims description 36
201000004681 Psoriasis Diseases 0.000 claims description 52
230000006872 improvement Effects 0.000 claims description 48
230000003902 lesion Effects 0.000 claims description 36
150000001875 compounds Chemical class 0.000 claims description 32
239000003814 drug Substances 0.000 claims description 32
238000000034 method Methods 0.000 claims description 29
239000005557 antagonist Substances 0.000 claims description 19
102000004127 Cytokines Human genes 0.000 claims description 15
108090000695 Cytokines Proteins 0.000 claims description 15
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 15
229960000485 methotrexate Drugs 0.000 claims description 15
230000002757 inflammatory effect Effects 0.000 claims description 10
150000003431 steroids Chemical class 0.000 claims description 9
230000000699 topical effect Effects 0.000 claims description 8
238000002560 therapeutic procedure Methods 0.000 claims description 7
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 6
108010036949 Cyclosporine Proteins 0.000 claims description 6
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 6
229960001265 ciclosporin Drugs 0.000 claims description 6
229930182912 cyclosporin Natural products 0.000 claims description 6
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
238000010254 subcutaneous injection Methods 0.000 claims description 6
239000007929 subcutaneous injection Substances 0.000 claims description 6
229960001940 sulfasalazine Drugs 0.000 claims description 6
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 6
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 6
239000012730 sustained-release form Substances 0.000 claims description 6
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 5
239000007943 implant Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 claims description 4
230000009885 systemic effect Effects 0.000 claims description 4
210000001744 T-lymphocyte Anatomy 0.000 claims description 3
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
229940035676 analgesics Drugs 0.000 claims description 3
239000000730 antalgic agent Substances 0.000 claims description 3
NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 claims description 3
229920000249 biocompatible polymer Polymers 0.000 claims description 3
239000011280 coal tar Substances 0.000 claims description 3
229960002311 dithranol Drugs 0.000 claims description 3
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
238000001126 phototherapy Methods 0.000 claims description 3
229960004889 salicylic acid Drugs 0.000 claims description 3
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
235000005282 vitamin D3 Nutrition 0.000 claims description 3
239000011647 vitamin D3 Substances 0.000 claims description 3
229940021056 vitamin d3 Drugs 0.000 claims description 3
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 claims description 2
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims description 2
102000018697 Membrane Proteins Human genes 0.000 claims description 2
108010052285 Membrane Proteins Proteins 0.000 claims description 2
229960001330 hydroxycarbamide Drugs 0.000 claims description 2
238000002616 plasmapheresis Methods 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
239000000203 mixture Substances 0.000 description 53
201000001263 Psoriatic Arthritis Diseases 0.000 description 50
208000036824 Psoriatic arthropathy Diseases 0.000 description 50
238000002648 combination therapy Methods 0.000 description 48
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 44
108060008682 Tumor Necrosis Factor Proteins 0.000 description 42
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 42
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 31
239000002451 tumor necrosis factor inhibitor Substances 0.000 description 31
239000000902 placebo Substances 0.000 description 27
108010008165 Etanercept Proteins 0.000 description 26
229940068196 placebo Drugs 0.000 description 26
208000035475 disorder Diseases 0.000 description 25
230000004044 response Effects 0.000 description 25
229960000403 etanercept Drugs 0.000 description 24
229940079593 drug Drugs 0.000 description 21
206010039073 rheumatoid arthritis Diseases 0.000 description 20
201000010099 disease Diseases 0.000 description 19
230000001185 psoriatic effect Effects 0.000 description 14
239000003112 inhibitor Substances 0.000 description 13
208000024891 symptom Diseases 0.000 description 11
210000004027 cell Anatomy 0.000 description 10
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 9
102100040247 Tumor necrosis factor Human genes 0.000 description 9
208000006820 Arthralgia Diseases 0.000 description 8
230000001684 chronic effect Effects 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 7
230000002159 abnormal effect Effects 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
210000001503 joint Anatomy 0.000 description 7
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
206010015150 Erythema Diseases 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
241000219061 Rheum Species 0.000 description 6
210000000988 bone and bone Anatomy 0.000 description 6
231100000321 erythema Toxicity 0.000 description 6
102000037865 fusion proteins Human genes 0.000 description 6
108020001507 fusion proteins Proteins 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 5
208000002193 Pain Diseases 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
206010003246 arthritis Diseases 0.000 description 5
230000006378 damage Effects 0.000 description 5
208000014674 injury Diseases 0.000 description 5
238000002483 medication Methods 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
108010074051 C-Reactive Protein Proteins 0.000 description 4
102100032752 C-reactive protein Human genes 0.000 description 4
206010011878 Deafness Diseases 0.000 description 4
201000004624 Dermatitis Diseases 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
206010023232 Joint swelling Diseases 0.000 description 4
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
102100036220 PC4 and SFRS1-interacting protein Human genes 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
230000002917 arthritic effect Effects 0.000 description 4
230000001363 autoimmune Effects 0.000 description 4
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
239000012634 fragment Substances 0.000 description 4
210000003128 head Anatomy 0.000 description 4
230000010370 hearing loss Effects 0.000 description 4
231100000888 hearing loss Toxicity 0.000 description 4
208000016354 hearing loss disease Diseases 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
238000005259 measurement Methods 0.000 description 4
210000000282 nail Anatomy 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
210000001258 synovial membrane Anatomy 0.000 description 4
206010006895 Cachexia Diseases 0.000 description 3
206010007558 Cardiac failure chronic Diseases 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
206010018364 Glomerulonephritis Diseases 0.000 description 3
208000019693 Lung disease Diseases 0.000 description 3
208000008589 Obesity Diseases 0.000 description 3
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 3
206010040844 Skin exfoliation Diseases 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000000539 dimer Substances 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
239000010931 gold Substances 0.000 description 3
230000036541 health Effects 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
230000008595 infiltration Effects 0.000 description 3
238000001764 infiltration Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000003278 mimic effect Effects 0.000 description 3
235000020824 obesity Nutrition 0.000 description 3
229940124583 pain medication Drugs 0.000 description 3
229960001476 pentoxifylline Drugs 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
201000007094 prostatitis Diseases 0.000 description 3
206010040882 skin lesion Diseases 0.000 description 3
231100000444 skin lesion Toxicity 0.000 description 3
235000002639 sodium chloride Nutrition 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
230000008961 swelling Effects 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
210000001179 synovial fluid Anatomy 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
230000000007 visual effect Effects 0.000 description 3
VDPLLINNMXFNQX-UHFFFAOYSA-N (1-aminocyclohexyl)methanol Chemical compound OCC1(N)CCCCC1 VDPLLINNMXFNQX-UHFFFAOYSA-N 0.000 description 2
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 description 2
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
208000023769 AA amyloidosis Diseases 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
208000032467 Aplastic anaemia Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 2
241000271566 Aves Species 0.000 description 2
208000037157 Azotemia Diseases 0.000 description 2
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
208000017667 Chronic Disease Diseases 0.000 description 2
206010064769 Dactylitis Diseases 0.000 description 2
208000002506 Darier Disease Diseases 0.000 description 2
206010015218 Erythema multiforme Diseases 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
206010060820 Joint injury Diseases 0.000 description 2
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
208000016593 Knee injury Diseases 0.000 description 2
208000012309 Linear IgA disease Diseases 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
208000030289 Lymphoproliferative disease Diseases 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical class [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
206010033645 Pancreatitis Diseases 0.000 description 2
208000000450 Pelvic Pain Diseases 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
241000669298 Pseudaulacaspis pentagona Species 0.000 description 2
102000014128 RANK Ligand Human genes 0.000 description 2
108010025832 RANK Ligand Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
201000002661 Spondylitis Diseases 0.000 description 2
206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
206010047115 Vasculitis Diseases 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
239000003430 antimalarial agent Substances 0.000 description 2
229940033495 antimalarials Drugs 0.000 description 2
238000011225 antiretroviral therapy Methods 0.000 description 2
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
229960002170 azathioprine Drugs 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
206010006475 bronchopulmonary dysplasia Diseases 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
208000013507 chronic prostatitis Diseases 0.000 description 2
229960004126 codeine Drugs 0.000 description 2
229960001338 colchicine Drugs 0.000 description 2
239000002131 composite material Substances 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000035618 desquamation Effects 0.000 description 2
229960004193 dextropropoxyphene Drugs 0.000 description 2
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
206010014910 enthesopathy Diseases 0.000 description 2
208000030533 eye disease Diseases 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
229910052737 gold Inorganic materials 0.000 description 2
238000001631 haemodialysis Methods 0.000 description 2
201000009277 hairy cell leukemia Diseases 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
230000000322 hemodialysis Effects 0.000 description 2
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
229960002764 hydrocodone bitartrate Drugs 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
208000036971 interstitial lung disease 2 Diseases 0.000 description 2
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
201000004607 keratosis follicularis Diseases 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
230000007774 longterm Effects 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
201000005962 mycosis fungoides Diseases 0.000 description 2
230000037311 normal skin Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
229940124624 oral corticosteroid Drugs 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
238000012261 overproduction Methods 0.000 description 2
229960003617 oxycodone hydrochloride Drugs 0.000 description 2
229960005489 paracetamol Drugs 0.000 description 2
208000025487 periodic fever syndrome Diseases 0.000 description 2
201000001245 periodontitis Diseases 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
208000005069 pulmonary fibrosis Diseases 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
210000004761 scalp Anatomy 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
229960003433 thalidomide Drugs 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
229960004380 tramadol Drugs 0.000 description 2
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
239000013638 trimer Substances 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
210000001364 upper extremity Anatomy 0.000 description 2
238000002562 urinalysis Methods 0.000 description 2
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
206010065040 AIDS dementia complex Diseases 0.000 description 1
208000023761 AL amyloidosis Diseases 0.000 description 1
206010000234 Abortion spontaneous Diseases 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010001014 Acute polyneuropathies Diseases 0.000 description 1
108010062271 Acute-Phase Proteins Proteins 0.000 description 1
102000011767 Acute-Phase Proteins Human genes 0.000 description 1
201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
235000002961 Aloe barbadensis Nutrition 0.000 description 1
244000144927 Aloe barbadensis Species 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000030760 Anaemia of chronic disease Diseases 0.000 description 1
208000000103 Anorexia Nervosa Diseases 0.000 description 1
208000036487 Arthropathies Diseases 0.000 description 1
208000033116 Asbestos intoxication Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
206010064539 Autoimmune myocarditis Diseases 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
208000027496 Behcet disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
208000006373 Bell palsy Diseases 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
208000019838 Blood disease Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
241000180135 Borrelia recurrentis Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
102000004634 CD30 Ligand Human genes 0.000 description 1
108010017987 CD30 Ligand Proteins 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
206010008089 Cerebral artery occlusion Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
206010008642 Cholesteatoma Diseases 0.000 description 1
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
208000000668 Chronic Pancreatitis Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010011026 Corneal lesion Diseases 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
206010012455 Dermatitis exfoliative Diseases 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
208000037408 Device failure Diseases 0.000 description 1
208000033998 Device material issue Diseases 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
206010072268 Drug-induced liver injury Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
208000009701 Embryo Loss Diseases 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010015278 Erythrodermic psoriasis Diseases 0.000 description 1
206010016207 Familial Mediterranean fever Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
208000015872 Gaucher disease Diseases 0.000 description 1
208000007465 Giant cell arteritis Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
206010058060 Graft complication Diseases 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
206010056557 Gulf war syndrome Diseases 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
241000208680 Hamamelis mollis Species 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
206010019728 Hepatitis alcoholic Diseases 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
208000031814 IgA Vasculitis Diseases 0.000 description 1
208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
206010021542 Implant site reaction Diseases 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
206010023369 Keratosis follicular Diseases 0.000 description 1
206010023439 Kidney transplant rejection Diseases 0.000 description 1
208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
102000016267 Leptin Human genes 0.000 description 1
108010092277 Leptin Proteins 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
206010027202 Meningitis bacterial Diseases 0.000 description 1
206010027260 Meningitis viral Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
206010067387 Myelodysplastic syndrome transformation Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
206010028561 Myeloid metaplasia Diseases 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
206010028703 Nail psoriasis Diseases 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
206010058116 Nephrogenic anaemia Diseases 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
208000003076 Osteolysis Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
206010033649 Pancreatitis chronic Diseases 0.000 description 1
208000009608 Papillomavirus Infections Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
201000011152 Pemphigus Diseases 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010071384 Peptide T Proteins 0.000 description 1
208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
206010035742 Pneumonitis Diseases 0.000 description 1
206010036030 Polyarthritis Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
206010036673 Primary amyloidosis Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
208000024777 Prion disease Diseases 0.000 description 1
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
208000037099 Prosthesis Failure Diseases 0.000 description 1
206010037075 Protozoal infections Diseases 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010037575 Pustular psoriasis Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
206010038272 Refractory anaemia with ringed sideroblasts Diseases 0.000 description 1
208000009527 Refractory anemia Diseases 0.000 description 1
208000033501 Refractory anemia with excess blasts Diseases 0.000 description 1
206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
206010038848 Retinal detachment Diseases 0.000 description 1
208000009921 Rheumatoid Nodule Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
208000008765 Sciatica Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
206010039811 Secondary amyloidosis Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
241000320380 Silybum Species 0.000 description 1
235000010841 Silybum marianum Nutrition 0.000 description 1
244000044822 Simmondsia californica Species 0.000 description 1
235000004433 Simmondsia californica Nutrition 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
206010040799 Skin atrophy Diseases 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
208000006045 Spondylarthropathies Diseases 0.000 description 1
231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
208000002667 Subdural Hematoma Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
208000010265 Sweet syndrome Diseases 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
208000004760 Tenosynovitis Diseases 0.000 description 1
206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010044688 Trisomy 21 Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
206010070517 Type 2 lepra reaction Diseases 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
208000036826 VIIth nerve paralysis Diseases 0.000 description 1
206010053648 Vascular occlusion Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000010796 X-linked adrenoleukodystrophy Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000001436 acantholytic effect Effects 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
229960005339 acitretin Drugs 0.000 description 1
206010000496 acne Diseases 0.000 description 1
208000013685 acquired idiopathic sideroblastic anemia Diseases 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
208000002353 alcoholic hepatitis Diseases 0.000 description 1
IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
235000011399 aloe vera Nutrition 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
208000022400 anemia due to chronic disease Diseases 0.000 description 1
208000010123 anthracosis Diseases 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
208000002399 aphthous stomatitis Diseases 0.000 description 1
206010003230 arteritis Diseases 0.000 description 1
206010003441 asbestosis Diseases 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
201000004995 autoimmune glomerulonephritis Diseases 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
201000009904 bacterial meningitis Diseases 0.000 description 1
239000008228 bacteriostatic water for injection Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
208000005980 beta thalassemia Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000000746 body region Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
229960002802 bromocriptine Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
208000000594 bullous pemphigoid Diseases 0.000 description 1
150000004648 butanoic acid derivatives Chemical class 0.000 description 1
229960002882 calcipotriol Drugs 0.000 description 1
LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
229960005084 calcitriol Drugs 0.000 description 1
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
229960002504 capsaicin Drugs 0.000 description 1
235000017663 capsaicin Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
231100000481 chemical toxicant Toxicity 0.000 description 1
229940112822 chewing gum Drugs 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
208000003167 cholangitis Diseases 0.000 description 1
208000019069 chronic childhood arthritis Diseases 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
210000000860 cochlear nerve Anatomy 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
208000021921 corneal disease Diseases 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
208000018180 degenerative disc disease Diseases 0.000 description 1
230000003210 demyelinating effect Effects 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
201000008865 drug-induced hepatitis Diseases 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
210000003027 ear inner Anatomy 0.000 description 1
208000002296 eclampsia Diseases 0.000 description 1
231100000557 embryo loss Toxicity 0.000 description 1
229940073621 enbrel Drugs 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
231100000317 environmental toxin Toxicity 0.000 description 1
210000005175 epidermal keratinocyte Anatomy 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
229960002199 etretinate Drugs 0.000 description 1
238000004299 exfoliation Methods 0.000 description 1
231100000573 exposure to toxins Toxicity 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
208000024711 extrinsic asthma Diseases 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
210000004996 female reproductive system Anatomy 0.000 description 1
231100000562 fetal loss Toxicity 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
210000004905 finger nail Anatomy 0.000 description 1
210000004904 fingernail bed Anatomy 0.000 description 1
-1 fish oils Substances 0.000 description 1
229940013317 fish oils Drugs 0.000 description 1
201000003444 follicular lymphoma Diseases 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
150000002237 fumaric acid derivatives Chemical class 0.000 description 1
230000004927 fusion Effects 0.000 description 1
229960002870 gabapentin Drugs 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
150000002343 gold Chemical class 0.000 description 1
229940076085 gold Drugs 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
206010018797 guttate psoriasis Diseases 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
208000003532 hypothyroidism Diseases 0.000 description 1
230000002989 hypothyroidism Effects 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
208000013617 idiopathic gastroparesis Diseases 0.000 description 1
208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
102000053460 interleukin-17 receptor activity proteins Human genes 0.000 description 1
108040001304 interleukin-17 receptor activity proteins Proteins 0.000 description 1
102000044166 interleukin-18 binding protein Human genes 0.000 description 1
108010070145 interleukin-18 binding protein Proteins 0.000 description 1
208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
208000023589 ischemic disease Diseases 0.000 description 1
229960005280 isotretinoin Drugs 0.000 description 1
150000002547 isoxazolines Chemical class 0.000 description 1
230000007803 itching Effects 0.000 description 1
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
229960000991 ketoprofen Drugs 0.000 description 1
229960004752 ketorolac Drugs 0.000 description 1
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
229940039781 leptin Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
238000010197 meta-analysis Methods 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
208000022949 middle ear disease Diseases 0.000 description 1
DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
229960004023 minocycline Drugs 0.000 description 1
229960005249 misoprostol Drugs 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 description 1
206010028537 myelofibrosis Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
201000003631 narcolepsy Diseases 0.000 description 1
201000011216 nasopharynx carcinoma Diseases 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
230000003448 neutrophilic effect Effects 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000010466 nut oil Substances 0.000 description 1
235000019488 nut oil Nutrition 0.000 description 1
208000014055 occupational lung disease Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000000771 oncological effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229960002739 oxaprozin Drugs 0.000 description 1
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
208000012111 paraneoplastic syndrome Diseases 0.000 description 1
230000007170 pathology Effects 0.000 description 1
201000001976 pemphigus vulgaris Diseases 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
201000010076 persian gulf syndrome Diseases 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
208000030428 polyarticular arthritis Diseases 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
230000008569 process Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
150000005599 propionic acid derivatives Chemical class 0.000 description 1
201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
208000008128 pulmonary tuberculosis Diseases 0.000 description 1
208000009954 pyoderma gangrenosum Diseases 0.000 description 1
JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
150000003217 pyrazoles Chemical class 0.000 description 1
150000004040 pyrrolidinones Chemical class 0.000 description 1
URMKWAIIKFEUKR-UHFFFAOYSA-N quinoline-2-sulfonamide Chemical class C1=CC=CC2=NC(S(=O)(=O)N)=CC=C21 URMKWAIIKFEUKR-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
208000023933 refractory anemia with excess blasts in transformation Diseases 0.000 description 1
208000007865 relapsing fever Diseases 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
201000006845 reticulosarcoma Diseases 0.000 description 1
208000029922 reticulum cell sarcoma Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
208000019793 rhegmatogenous retinal detachment Diseases 0.000 description 1
229960000371 rofecoxib Drugs 0.000 description 1
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
201000004700 rosacea Diseases 0.000 description 1
229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
150000003872 salicylic acid derivatives Chemical class 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
201000002859 sleep apnea Diseases 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
SDKPSXWGRWWLKR-UHFFFAOYSA-M sodium;9,10-dioxoanthracene-1-sulfonate Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)[O-] SDKPSXWGRWWLKR-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
208000000995 spontaneous abortion Diseases 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
208000025889 stromal keratitis Diseases 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
230000001629 suppression Effects 0.000 description 1
210000002437 synoviocyte Anatomy 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000011269 tar Substances 0.000 description 1
206010043207 temporal arteritis Diseases 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
201000005060 thrombophlebitis Diseases 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
229940126702 topical medication Drugs 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
210000002229 urogenital system Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000021331 vascular occlusion disease Diseases 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
201000010044 viral meningitis Diseases 0.000 description 1
206010047470 viral myocarditis Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
229940118846 witch hazel Drugs 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physical Education & Sports Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU43632/00A 1999-04-19 2000-04-19 Soluble tumor necrosis factor receptor treatment of medical desorders Abandoned AU4363200A (en)

Applications Claiming Priority (15)

Application Number	Priority Date	Filing Date	Title
US13007499P	1999-04-19	1999-04-19
US60130074		1999-04-19
US13432099P	1999-05-14	1999-05-14
US60134320		1999-05-14
US14395999P	1999-07-15	1999-07-15
US60143959		1999-07-15
US14823499P	1999-08-11	1999-08-11
US60148234		1999-08-11
US37382899A	1999-08-13	1999-08-13
US09373828		1999-08-13
US16467699P	1999-11-10	1999-11-10
US60164676		1999-11-10
US18486400P	2000-02-25	2000-02-25
US60184864		2000-02-25
PCT/US2000/010565 WO2000062790A2 (fr)	1999-04-19	2000-04-19	Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble

Publications (1)

Publication Number	Publication Date
AU4363200A true AU4363200A (en)	2000-11-02

Family

ID=27568861

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU43632/00A Abandoned AU4363200A (en)	1999-04-19	2000-04-19	Soluble tumor necrosis factor receptor treatment of medical desorders

Country Status (4)

Country	Link
EP (1)	EP1171148A2 (fr)
AU (1)	AU4363200A (fr)
CA (1)	CA2366785C (fr)
WO (1)	WO2000062790A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3443119B2 (ja)	1989-08-07	2003-09-02	ペプテックリミテッド	腫瘍壊死因子結合リガンド
US20030225254A1 (en)	1989-08-07	2003-12-04	Rathjen Deborah Ann	Tumour necrosis factor binding ligands
US7192584B2 (en)	1991-03-18	2007-03-20	Centocor, Inc.	Methods of treating psoriasis with anti-TNF antibodies
US7091181B2 (en)	1994-12-12	2006-08-15	Omeros Corporation	Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US7067144B2 (en)	1998-10-20	2006-06-27	Omeros Corporation	Compositions and methods for systemic inhibition of cartilage degradation
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
CA2704600C (fr)	1999-04-09	2016-10-25	Kyowa Kirin Co., Ltd.	Methode de production d'anticorps avec activite adcc accrue
EP1261364A1 (fr) *	2000-02-10	2002-12-04	Wyeth	Procede destine a traiter ou a inhiber des lesions ou des morts cellulaires
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2425506A1 (fr) *	2000-10-18	2002-08-01	Immunex Corporation	Methodes de traitement de la polyarthrite rhumatoide a l'aide d'antagonistes de l'il-17
BRPI0209933B8 (pt)	2001-05-24	2021-05-25	Zymogenetics Inc	proteína de fusão, e, molécula de ácido nucleico
WO2003009864A1 (fr) *	2001-07-23	2003-02-06	Genset S.A.	Agonistes et antagonistes de disomet pour le traitement de troubles metaboliques
GB0128138D0 (en) *	2001-11-23	2002-01-16	King S College London	Pharmaceutical use
SI1478394T1 (sl)	2002-02-27	2008-12-31	Immunex Corp	STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
EP3210624A1 (fr)	2002-02-27	2017-08-30	Immunex Corporation	Composition tnfr-fc stabilisée comportant de l'arginine
JPWO2005035586A1 (ja) *	2003-10-08	2007-11-22	協和醗酵工業株式会社	融合蛋白質組成物
NZ595225A (en)	2005-05-16	2013-05-31	Abbott Biotech Ltd	Use of tnf inhibitor for treatment of erosive polyarthritis
BRPI0611901A2 (pt)	2005-06-14	2012-08-28	Amgen, Inc	composição, liofilizado, kit, e, processo para preparar uma composição
WO2007019573A2 (fr)	2005-08-09	2007-02-15	Zymogenetics, Inc.	Procedes pour le traitement et la prevention de proliferation cellulaire anormale par le biais de molecules de fusion taci
EP1922080A2 (fr)	2005-08-09	2008-05-21	ZymoGenetics, Inc.	Procedes destines au traitement des malignites des lymphocytes b au moyen d'une molecule de fusion taci-ig
WO2007082542A1 (fr) *	2006-01-17	2007-07-26	Astion Pharma A/S	Préparations comprenant de l’oxaprozine et un analogue de vitamine d3 et leur emploi dans la fabrication d'un médicament pour le traitement du psoriasis
US9605064B2 (en)	2006-04-10	2017-03-28	Abbvie Biotechnology Ltd	Methods and compositions for treatment of skin disorders
WO2007121538A1 (fr) *	2006-04-26	2007-11-01	Plasma Ventures Pty Ltd	Produit sanguin anti-inflammatoire et procede d'utilisation
BRPI0711823A2 (pt)	2006-05-15	2012-01-17	Ares Trading Sa	métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
EP2699265B1 (fr)	2011-04-20	2019-10-16	Sandoz AG	Formulations liquides pharmaceutiques stables de la protéine de fusion tnfr:fc
CN103930124B (zh) *	2011-07-01	2021-05-11	生物基因Ma公司	无精氨酸的tnfr：fc-融合多肽组合物及使用方法
US10485869B2 (en)	2011-10-18	2019-11-26	Coherus Biosciences, Inc.	Etanercept formulations stabilized with meglumine
BR112014009146A8 (pt)	2011-10-18	2017-06-20	Coherus Biosciences Inc	formulações de etanercepte estabilizadas com aminoácidos
HK1209343A1 (en) *	2012-07-09	2016-04-01	Coherus Biosciences, Inc.	Etanercept formulations exhibiting marked reduction in sub-visible particles
SI2895188T1 (en)	2012-09-11	2018-05-31	Coherus Biosciences, Inc.	CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE
US20160017021A1 (en)	2013-03-06	2016-01-21	Protalix Ltd.	TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
EP3268042B1 (fr)	2015-03-13	2024-11-27	Samsung Bioepis Co., Ltd.	Composition contenant un polypeptide anti-tnf-alpha et utilisation
US20180311199A1 (en) *	2016-01-12	2018-11-01	Lawrence Chan	Combination treatment for inflammatory diseases
PT3528787T (pt)	2016-10-21	2026-03-11	Amgen Inc	Formulações farmacêuticas e métodos para produzir as mesmas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998024463A2 (fr) *	1996-12-06	1998-06-11	Amgen Inc.	Therapie combinatoire utilisant une proteine de liaison du facteur de necrose tumorale (tnf) dans le traitement de maladies induites par le tnf
EP0869179A1 (fr) *	1997-04-02	1998-10-07	Smithkline Beecham Corporation	Récepteur en rapport avec la nécrose des tumeurs, TR7

2000
- 2000-04-19 EP EP00923525A patent/EP1171148A2/fr not_active Withdrawn
- 2000-04-19 WO PCT/US2000/010565 patent/WO2000062790A2/fr not_active Ceased
- 2000-04-19 AU AU43632/00A patent/AU4363200A/en not_active Abandoned
- 2000-04-19 CA CA2366785A patent/CA2366785C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
WO2000062790A8 (fr)	2001-08-02
WO2000062790A2 (fr)	2000-10-26
WO2000062790A3 (fr)	2001-07-12
EP1171148A2 (fr)	2002-01-16
CA2366785A1 (fr)	2000-10-26
CA2366785C (fr)	2012-02-07

Publication	Publication Date	Title
CA2366785C (fr)	2012-02-07	Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble
US7915225B2 (en)	2011-03-29	Soluble tumor necrosis factor receptor treatment of medical disorders
US20090022733A1 (en)	2009-01-22	Methods for treating Disease with an IL-1R antibody
AU2002324625B2 (en)	2008-05-08	Interleukin-1 receptors in the treatment of diseases
AU2002324625A1 (en)	2003-06-19	Interleukin-1 receptors in the treatment of diseases
ES2207759T3 (es)	2004-06-01	Terapia de combinacion que utiliza una proteina de union del factor de necrosis tumoral (tnf) en el tratamiento de enfermedades inducidas por el tnf.
US20030148955A1 (en)	2003-08-07	Soluble tumor necrosis factor receptor treatment of medical disorders
US20090297517A1 (en)	2009-12-03	Methods for treating il-18 mediated disorders
US20010021380A1 (en)	2001-09-13	Soluble tumor necrosis factor receptor treatment of medical disorders
JP2007521315A (ja)	2007-08-02	結晶性腫瘍壊死因子レセプター２ポリペプチド
WO2015138638A1 (fr)	2015-09-17	Agonistes de récepteur de protéine trail à action prolongée pour le traitement de maladies auto-immunes
WO2001037874A2 (fr)	2001-05-31	Traitement du psoriasis
JP2007517021A (ja)	2007-06-28	長いペントラキシンｐｔｘ３の阻害剤を含む医薬
EP1419236A2 (fr)	2004-05-19	Methodes de traitement ou de prevention de troubles sclereux par l'usage d'agents se liant a cd2
CA2577883A1 (fr)	2006-02-23	Proteine de liaison au tnf de type 1 dans le traitement du psoriasis